Corporate VCs Step Up Carefully to Fill VC Void

As institutional venture firms gird themselves for difficult times ahead in raising new funds, investment programs at pharmaceutical companies and large medical device companies are at least partially filling the gap by committing corporate dollars into private life sciences companies, even in earlier stages.

More from Archive

More from In Vivo